Sage — Strength · Strength-volume / hypertrophy

Capacity III of IV — Strength-volume / hypertrophy

This page owns mechanical tension → mTORC1 → hypertrophy and mitochondrial network volume (Axis 1). Surfer anchor #strength-hypertrophy. Program cards stay on the Strength hub. No invent set-rep medical Rx.

From dual-pathway Axis 1

Axis 1 — Mechanical tension to mTORC1 to hypertrophy and strength

High mechanical tension, especially near maximal effort with long rest intervals, strongly activates mTORC1. Downstream, S6K1 and 4E-BP1 phosphorylation increase translational capacity. Ribosome biogenesis expands the factory that will later assemble myosin and actin. Satellite-cell and myonuclear contributions matter over longer horizons, but the acute and early-chronic program is tension plus amino acids plus enough ATP to pay for translation.

This is why the ARX session is built as it is. Accommodating resistance matches force to the strength curve as fatigue accumulates, so the fiber is kept near a high-tension state without the usual sticking-point underload of a barbell. One set of four repetitions per movement, taken toward fatigue, with four minutes between sets, keeps the work on the phosphocreatine system. The session is creatine-P dominant by design. Long rests are not laziness. They are the condition that prevents the mTOR day from becoming an accidental glycolytic interval day. Metabolic interference on the strength day is treated as contamination of the signal.

Musculotendinous tension, not OXPHOS, is what speaks mTOR

mTORC1 in adult skeletal muscle is first a mechanosensor pathway. It is not an aerobic pathway. Steady OXPHOS work can keep a fiber alive and even help pay the later ATP bill of translation, but it is a weak and unreliable way to turn mTORC1 on. The signal that does so, in this protocol, is high force transmitted through the muscle-tendon unit: actin-myosin cross-bridges under load, extracellular matrix strain, costameres, and the myotendinous junction.

The fiber reads that strain at several hardware layers. Integrins and the dystrophin-associated complex couple the sarcomere to the basement membrane. Focal adhesion kinase and related adhesion plaques convert that geometry into phosphorylation. Titin, spanning the sarcomere, changes conformation under stretch and is increasingly treated as a length and force reporter. At the membrane, mechanical loading activates phospholipase D and raises phosphatidic acid, a lipid that can bind and help activate mTORC1. Loaded tension also favors mTORC1 residence at the lysosome, where Rheb can turn it on—provided amino acids, especially leucine, later complete the nutrient half of the conversation.

Tendon and intramuscular connective tissue are not spectators. Tenocytes and the myotendinous junction experience the same force line. They adapt on a slower clock than myofibrils, which is one reason low-volume, high-tension work with long rest is kinder than high-repetition grinding: the collagen matrix is loaded honestly without being turned into an inflammatory overtime shift. The protocol is not a tendon-rehab essay. It is an essay that refuses to pretend muscle can be grown by metabolic noise while the force-bearing line is underloaded.

This is why aerobic activity and OXPHOS flux are the wrong tools for Axis 1. A long row or a Zone-2 ride raises oxygen consumption and can even raise some mitochondrial transcripts. It does not put near-maximal tension through the costamere for a few high-quality seconds, rest long enough for phosphocreatine to return, and repeat that language five times. When energy charge falls hard during the lift itself, AMPK rises and can restrain mTORC1 through TSC2 and raptor. That is the molecular version of the interference effect. The ARX prescription—four reps, four minutes, creatine-P dominant—is an attempt to keep the adenylate pool from becoming the story on the day that stretch and tension should be the story.

Passive stretch without high active tension is also incomplete. Length matters; force through the cross-bridge and the tendon matters more. Accommodating resistance is useful here because it keeps tension high through ranges where a barbell would unload. A four-rep set that stays heavy in the strong part of the curve is more mTOR language per minute than a twenty-rep set that became an AMP problem after repetition eight.

Hypertrophy is net myofibrillar accretion, not soreness. Exercise raises both synthesis and degradation. Early in a block, much of the apparent work is damage control—chaperone-assisted selective autophagy, BAG3, CRYAB, local suppression of mTOR at lesion sites so wrecked sarcomeric proteins can be cleared. Growth proper arrives when lesion burden falls and the same tension can be applied to a stable structure. That is one reason the protocol refuses high-volume grinding: damage is a tax, not the stimulus. A mid-life trainee who manufactures unnecessary lesion burden spends the rest week paying the tax instead of depositing protein.

Mitochondria are not spectators to this axis. Translation and ribosome biogenesis are ATP-expensive. A fiber that cannot meet the energy cost of making ribosomes will not sustain hypertrophy no matter how perfect the machine setup. The dual-pathway week therefore does not treat oxidative capacity as a separate hobby. It treats the SIRT1 days as the construction of the power plant that will later underwrite the mTOR days.

Why mid-life volume must be frugal

Concurrent-training literature is full of programs that try to collect every adaptation in the same session or the same afternoon: heavy squat, then intervals, then a pump, then a Zone-2 finish. That is a young person's surplus and a mid-life person's overreach. Residual fatigue from metabolic work degrades the next high-tension session. Residual neural and tissue strain from high-tension work blunts the quality of a sprint that is no longer maximal. The dual-pathway design assumes recovery realities after forty: one uncontested mTOR day, protected by rest on both sides, and metabolic work delivered as single deep efforts rather than as accumulated interval volume. The hypothesis is that depth of energy-charge disruption, not minutes in the red, is the SIRT1 driver—and that protecting ARX quality is worth more than adding a second lift day that arrives under-recovered.

Seven-day map note

Hypertrophy

Day 1 ARX plus the Day-1 daylight protein meal plus the Day-2 protected window. mTORC1, ribosomes, myofibrillar synthesis. Dynamic accommodating resistance, low volume, long rest, phosphocreatine-dominant. No metabolic work on that day. No second lift day to soothe the anxiety that one set cannot be enough. One high-quality set to fatigue on an accommodating machine is not one sloppy set of twelve on a poorly loaded bar.

Neighbors

Biogenesis · Mitophagy — Axis 2 partners; complementarity, not same-hour max.
Hormesis timing — when tension is lawful.
Strength hub — week specification.

A working hypothesis, open to correction and revised as new evidence arrives. Last revised October 17, 2026.

Coach — Strength-volume · Strength hub

Related on Surf Wax: Grip dynamometer.